8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported) October 11, 2005

                    Hercules Technology Growth Capital, Inc.
             ------------------------------------------------------
             (Exact Name of Registrant as Specified in its Charter)

           Maryland                   000-51174                 74-3113410
 ----------------------------        -----------          ----------------------
 (State or other jurisdiction        (Commission              (IRS Employer
      of incorporation)              File Number)         Identification Number)

 525 University Avenue, Suite 700, Palo Alto, CA                  94301
 -----------------------------------------------                 --------
     (Address of principal executive offices)                    zip code

         Registrant's telephone number, including area code 650/289-3060


         --------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities
     Act (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange
     Act (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

================================================================================


ITEM 8.01 OTHER EVENTS

On October 11, 2005, Hercules Technology Growth Capital, Inc. announced $7.5M
Financing to Predicant Biosciences.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c)  Exhibits

99.1 Press release dated October 11, 2005



                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                        HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

October 11, 2005

                                        /s/ SCOTT HARVEY
                                        ----------------------------------------
                                        Scott Harvey
                                        Chief Legal Officer



                                  EXHIBIT INDEX

EXHIBIT NO.    DESCRIPTION OF EXHIBITS
- -----------    -------------------------------------
   99.1        Press Release dated October 11, 2005.

EX-99.1

                                                                    Exhibit 99.1

           HERCULES PROVIDES $7.5M FINANCING TO PREDICANT BIOSCIENCES

     PALO ALTO, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Hercules Technology
Growth Capital, Inc. (Nasdaq: HTGC), a leading debt and equity growth capital
provider to technology and life science companies, today announced that on Sept.
30, 3005 it provided $7.5 million of debt financing to Predicant Biosciences, an
emerging life sciences company developing minimally invasive technology for
identifying and assaying protein biomarkers. Proceeds from the financing will be
used to help Predicant develop and market technology that will provide
physicians with new, high-value tests for detecting, diagnosing and monitoring
complex disease states.

     (Logo: http://www.newscom.com/cgi-bin/prnh/20050609/SFTH149LOGO )

     "Predicant's technology can be used to detect disease at its earliest
stage, track disease progression, improve the accuracy of diagnosis and predict
the efficacy of therapy," said Kathy Conte, managing director of Hercules. "We
are pleased to partner with the company as it continues to develop an integrated
system to provide reliable measurements for protein pattern discovery and
clinical assay."

     Predicant was formed on the belief that the ability to define and monitor
biological states through the analysis of bodily fluids will lead to a
revolution in medicine and biomedical research. The company is working to become
the world leader in the field of proteomics. Led by an experienced management
team, Predicant seeks to transform the possibilities of its technologies into
improved realities for patients.

     About Hercules Technology Growth Capital:
     Founded in December 2003, Hercules Technology Growth Capital, Inc. is a
NASDAQ traded specialty finance company providing debt and equity growth capital
to technology and life sciences companies at all stages of development. The
company primarily finances privately held companies backed by leading venture
capital and private equity firms and also may finance certain publicly traded
companies. Hercules focuses its investments in industries such as computer
software and hardware, networking systems, semiconductors, semiconductor capital
equipment, information technology infrastructure, Internet consumer and business
services, telecommunications, and life sciences. The company's investments are
originated through its principal office located in the Silicon Valley, as well
as additional offices in the Boston, Boulder and Chicago areas. Providing
capital to privately held companies backed by leading venture capital and
private equity firms involves a certain degree of credit risk and may result in
potential losses.

     For more information, please visit http://www.herculestech.com . Companies
interested in learning more about financing opportunities should contact
info@herculestech.com or call 650-289-3060.

     About Predicant Biosciences:
     Founded in 2002, Predicant Biosciences is developing minimally invasive
technology for identifying and assaying protein biomarker patterns that reflect
and differentiate biological states. The integrated Predicant system consists of
proprietary separation, detection and informatics technologies, and is targeted
for use in diagnosing and managing disease states or drug development. Predicant
is headquartered in South San Francisco, CA. Additional information about
Predicant Biosciences is available at http://www.predicant.com .

CONTACT:  Hercules Technology Growth Capital, Inc., +1-650-289-3060, or
info@herculestech.com; or Deborah Stapleton, +1-650-470-0200, or
deb@stapleton.com/
Web site:  http://www.predicant.com /
Web site:  http://www.herculestech.com /